The low and middle income countries opioid substitution therapy market is expected to develop at a CAGR of 7.4% during the forecast period. The market value is projected to increase from US$ 805.2 million in 2024 to US$ 1,622.1 million by 2034. The low and middle income countries opioid substitution therapy market is valued at US$ 750.2 million at the end of 2023.
Key Highlight
| Attributes | Details |
|---|---|
| Estimated Market Size, 2024 | US$ 805.2 million |
| Expected Market Size, 2034 | US$ 1,622.1 million |
| Value CAGR (2024 to 2034) | 7.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Opioid substitution therapy has emerged as a crucial evidence-based approach for effectively managing opioid dependence. It is gaining increasing prominence in low and middle income countries (LMICs). The choice of drugs for this therapy varies across countries, contingent upon prescription regulations and approvals from relevant regulatory bodies.
Buprenorphine and methadone have garnered widespread acceptance as the treatment of choice, primarily attributed to their availability in diverse formulations, strengths, and brands. It's noteworthy that naloxone and naltrexone, both serving as opioid blockers, play distinct roles in the spectrum of substance use disorder management.
Naloxone, with its rapid-acting nature, is designed as an emergency intervention to reverse the effects of opioid overdose swiftly. Conversely, naltrexone assumes a different role. It is not intended for overdose situations. Instead, it is prescribed as a daily or monthly medication for addressing alcohol use disorder or opioid use disorder as part of ongoing treatment.
Naloxone functions as a critical tool for emergency scenarios, providing rapid response in overdose situations. On the other hand, naltrexone serves as a maintenance medication for the sustained treatment of substance use disorders. The introduction of generic and over-the-counter (OTC) products is poised to enhance accessibility to appropriate treatment, contributing to a forecasted reduction in mortality rates. This development marks a significant stride toward ensuring effective and accessible solutions in the landscape of opioid dependence management.
The low and middle-income countries' opioid substitution therapy market recorded a historic CAGR of 5.1% in the last five years from 2019 to 2023.
Opioid use disorder (OUD) stands as a significant global health challenge, contributing to heightened rates of premature mortality and morbidity. Within the framework of comprehensive OUD treatment (OUDT), opioid substitution therapy has gained approval. Opioid use disorders have a significant global impact, affecting over 16 million individuals. The prevalence of opioid use and dependency exhibits variations based on age and gender. Opioid-related deaths are more prevalent in older age groups, particularly between the ages of 40 and 50. However, heroin overdoses peak among individuals aged 20 to 30.
| Attributes | Details |
|---|---|
| Low and Middle Income Countries Opioid Substitution Therapy Market Size, 2023 | US$ 750.2 million |
The widespread prevalence of chronic pain and the concurrent issue of prescription opioid abuse have significant implications for patients, healthcare providers, and society at large. Opioid treatment programs (OTPs) play a vital role in addressing these challenges by offering medication-assisted treatment (MAT) for individuals diagnosed with opioid use disorder (OUD). Increasing prevalence and awareness stand out as crucial factors propelling market growth in low and middle-income countries.
Principal Consultant
Companies dedicated to opioid substitution therapy are actively developing and introducing novel goods and technologies. They aim to improve accessibility to treatment and diagnostic procedures in low and middle-income countries. This trend has resulted in an increased demand for opioid substitution therapy.
The evolution of therapeutic molecules goes hand in hand with advancements in drug delivery technologies. Innovative delivery systems bring a host of advantages to the medical field. These include enhanced bioavailability, making them well-suited for the long-term treatment of chronic illnesses. Additionally, such systems contribute to sustained maintenance of drug levels, reduced adverse effects, lower dosage requirements, improved patient compliance, minimized damage to healthy tissues, and the potential for cost reductions by developing new delivery systems for existing molecules. Currently, trending drug delivery mechanisms include implants, self-injectable, prefilled syringes, injectable pens, and others.
Over the past decade, a lot of innovation has occurred in injectable therapeutics. For instance, notable manufacturer Rusan Pharma introduced a wide range of product offerings in opioid substitution therapy, one of which is Verso (Naloxone), which is available in prefilled, injectable pen and vial forms.
The emergence of this innovative drug delivery technology and formulations presents promising business prospects for the opioid substitution therapy market in low and middle income countries.
The unmet medical needs in rural areas underscore the pressing necessity for improved healthcare access and resources, highlighting disparities that must be addressed to ensure comprehensive and equitable healthcare coverage. In rural parts, substance use patterns show higher rates of tobacco and methamphetamine use among adults, while opioid use has proliferated in towns of varying sizes.
Rural adolescents and young adults tend to exhibit elevated rates of alcohol consumption and engage in risky behaviors like binge drinking and driving under the influence more frequently than their urban counterparts. The battle against substance use in rural communities is complicated by resource limitations for prevention, treatment, and recovery. Multiple factors contribute to this situation, such as limited access to education, financial hardships, joblessness, inadequate availability of mental health support, experiences of isolation and despair, and higher societal stigma around mental health and substance use issues.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Countries | CAGR from 2024 to 2034 |
|---|---|
| Brazil | 3.0% |
| China | 8.4% |
| India | 4.1% |
| Malaysia | 13.6% |
| Georgia | 14.3% |
Brazil dominated the low and middle-income market as of 2023. With the anticipation of sustaining this momentum, Brazil is expected to demonstrate persistent high growth throughout the forecast period.
Over the past four decades, Brazil has witnessed a steady rise in urban violence and crime, a trend persisting despite positive strides in the nation's social and economic conditions. This surge is closely connected to the escalating domestic drug consumption, prompting significant shifts in the structure, profile, and modus operandi of organized crime groups. The intertwining issues of violence and criminality find a nexus in the operations of organized crime groups engaged in arms and drug trafficking.
Brazil, currently hosting the world's fourth-leading incarcerated population, underscores the urgency for alternative approaches to address the complex challenges of violence and crime, especially in the context of drug consumption. Efforts to navigate these issues require a comprehensive strategy that considers the interconnected factors contributing to the intricate landscape of crime and violence in the country.
In 2023, India held dominant revenue in the low and middle-income market, contributing around US$ 87.25 million.
About 2.1% of India's population is grappling with opioid use, encompassing substances like opium and its derivatives such as poppy husk, heroin (or its impure forms like smack or brown sugar), and various pharmaceutical opioids. Nationally, heroin emerges as a widespread opioid (1.14%), followed by pharmaceutical opioids (0.96%) and opium (0.52%). Notably, Nagaland, Arunachal Pradesh, Manipur, Sikkim, and Mizoram exhibit the highest prevalence of opioid use among the general population, surpassing 10%. The growing concern surrounding opioid consumption in India necessitates targeted interventions and public health initiatives to address the escalating trend.
Georgia's healthcare system benefits significantly from its access to healthcare supplies and assistance provided by established European countries. This collaboration fosters the exchange of medical resources, expertise, and support, enhancing Georgia's ability to address healthcare challenges effectively. This interconnected network of support reflects a commitment to regional health cooperation and underscores the importance of collective efforts in promoting the well-being of populations across borders.
| Drug Class | CAGR from 2024 to 2034 |
|---|---|
| Opioid Antagonists | 9.4% |
| Opioid Agonists and Partial Agonists | 6.6% |
The market value of opioid agonists and partial agonists in low and middle-income countries for opioid substitution therapy is US$ 588.5 million, representing a sizable 73.6% market share in 2023. The credibility of the drug's mode of action plays a pivotal role. Given its comparatively lower efficacy, buprenorphine is widely suitable for individuals with mild to moderate dependence. In contrast, methadone is applicable across all levels of support.
| Indication | CAGR from 2024 to 2034 |
|---|---|
| Pain Management | 13.1% |
| Opioid Withdrawal/Opioid Use Disorder (OUD) | 6.5% |
The market value of opioid withdrawal/opioid use disorder (OUD) in low and middle-income countries for opioid substitution therapy is US$ 649.2 million, representing a sizable 86.6% market share in 2023. The prevalence of opioid use disorders, along with the complex nature of withdrawal symptoms, underscores the urgency and necessity of effective interventions and treatments within the broader healthcare landscape. As a result, the demand for solutions addressing opioid withdrawal and use disorder remains high, making it a dominant component in the spectrum of pain management, alcohol de-addiction, and mental health care.
| Distribution Channel | CAGR from 2024 to 2034 |
|---|---|
| Government-supported Centers/NGO’s/Tenders | 6.3% |
| Institutional Sales | 10.2% |
The government-supported centers/NGOs/tenders have a considerable presence in the low and middle-income countries' opioid substitution therapy market, accounting for 80.5% of end users in 2023. The elevated significance of government-supported centers/NGOs/tenders in claiming the highest share stems from their crucial role in extending treatment accessibility at reduced costs. Additionally, entities funded through these channels often can provide treatment at no cost, further emphasizing their central role in ensuring widespread and affordable healthcare options.
Market players commit resources to advance research and development, aiming to integrate innovative features, technologies, and improvements into their opioid substitution therapy. Furthermore, industry players strategically emphasize expanding their influence in key geographic regions. This strategic expansion entails initiatives such as establishing new distribution channels, fostering partnerships with local distributors, or setting up subsidiaries in strategically advantageous locations for the effective distribution and accessibility of opioid substitution therapy solutions.
| Attribute | Details |
|---|---|
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2018 to 2023 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | Latin America, China, South Asia and Pacific, Europe, Arica, Central Asia |
| Key Countries Covered | Brazil, Peru, China, India, Vietnam, Afghanistan, Bangladesh, Cambodia, Myanmar, Nepal, Pakistan, Malaysia, Thailand, Ukraine, Georgia, Armenia, Kyrgyzstan, Kazakhstan, Tajikistan, South Africa, Nigeria, Egypt, Tanzania, Ghana, Kenya, Mozambique, Senegal, Uganda, Côte d'Ivoire (Ivory Coast), and the Rest of the low and middle income countries |
| Key Market Segments Covered | Drug Class, Indication, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is currently valued at around US$ 750.2 million in 2023.
The market is set to reach a valuation of around US$ 1,622.1 million by the end of 2034.
The opioid and partial agonists segment, within the drug class segment, held a 73.6% market share in 2023.
Demand for opioid substitution therapy in low and middle income countries increased at a 5.1% CAGR from 2019 to 2023.
The estimated market value for 2024 is around US$ 805.2 million.
Brazil accounts for around 13.8% share of the market in 2023.
India holds about 11.6% market share in the market in 2023.
Georgia accounted for a market value share of around 1.9% in 2023.
1. Market Overview
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Development/Innovation Trends
4. Value-Added Insights
4.1. Opioid Use Disorder and Global Overview
4.2. Disease Epidemiology Data, By Region
4.3. Drug Adoption / Usage Analysis, by Region
4.4. Pipeline Assessment
4.5. Singular Breakthroughs of Buprenorphine
4.6. Regulations Landscape
4.7. PESTEL Analysis
4.8. Porter’s Analysis
4.9. Value Chain Analysis, By Region
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. R&D funding By Region
5.1.3. R&D funding By Country
5.1.4. Pharmaceutical Spending
5.1.5. Expenditure on Retail Pharmaceuticals Per Capita
5.1.6. Parent Market Analysis
5.2. Forecast Factors - Relevance & Impact
5.2.1. Recent Developments In Management of Opioid Use
5.2.2. Rising Prevalence of OUD
5.2.3. Treatment Seeking Rate
5.2.4. High Unmet Medical Needs
5.2.5. Illicit Drug Dependence or Abuse
5.2.6. Ongoing Active Clinical Trials
5.2.7. Increasing Number of Programs
5.2.8. Regulatory Scenario
5.2.9. Diagnosis Rate
5.2.10. Drug Delivery Technology
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Market Demand (in Volume (Units) Analysis 2018 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market Volume (Units) Analysis, 2018 to 2023
6.2. Current and Future Market Volume (Units) Projections, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
7. Market – Pricing Assessment
7.1. Regional Pricing Analysis, By Product
7.2. Pricing Break-up
7.2.1. Manufacturer Level Pricing
7.2.2. Distributor Level Pricing
7.3. Global Average Pricing Analysis Benchmark, By Product
7.3.1. Pricing Assumptions
8. Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2023 and Forecast, 2024 to 2034
8.1. Revenue Opportunity Analysis
8.2. Historical Market Value (US$ Million) and Volume (Unit) Analysis, 2018 to 2023
8.3. Current and Future Market Value (US$ Million) and Volume (Unit) Projections, 2024 to 2034
8.3.1. Y-o-Y Growth Trend Analysis
8.3.2. Absolute $ Opportunity Analysis
9. Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) & Market Volume(Unit) Analysis, By Drug Class, 2018 to 2023
9.3. Current and Future Market Size (US$ Million) & Market Volume(Unit) and Forecast By Drug Class, 2024 to 2034
9.3.1. Opioid Antagonists
9.3.1.1. Naltrexone
9.3.1.2. Naloxone
9.3.2. Opioid Agonists and Partial Agonists
9.3.2.1. Methadone
9.3.2.2. Buprenorphine
9.4. Market Attractiveness Analysis By Drug Class
10. Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) By Indication, 2018 to 2023
10.3. Current and Future Market Size (US$ Million) and Analysis and Forecast By Indication, 2024 to 2034
10.3.1. Pain Management
10.3.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
10.3.3. Alcohol De-addiction
10.3.4. Depression
10.4. Market Attractiveness Analysis By Indication
11. Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) By Distribution Channel, 2018 to 2023
11.3. Current and Future Market Size (US$ Million) and Analysis and Forecast By Distribution Channel, 2024 to 2034
11.3.1. Government Supported Centers/NGO’s/Tenders
11.3.2. Institutional Sales
11.3.2.1. Hospitals
11.3.2.1.1. Private Hospitals
11.3.2.1.2. Public Hospitals
11.3.2.2. Psychiatric clinics
11.3.2.2.1. Private Clinics
11.3.2.2.2. Public Clinics
11.3.3. Retail Sales
11.3.3.1. Retail Pharmacies
11.3.3.2. Drug Store
11.3.3.3. Online Sales/Mail Order Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Trend Analysis by Region, 2018 to 2023
12.3. Current and Future Market Size (US$ Million) and Forecast by Region, 2024 to 2034
12.3.1. Latin America
12.3.2. Europe
12.3.3. China
12.3.4. Central Asia
12.3.5. South Asia and Pacific
12.3.6. Middle East and Africa
12.4. Market Attractiveness Analysis by Region
13. Latin America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023
13.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Peru
13.3.1.3. Rest of Latin America
13.3.2. By Drug Class
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Class
13.4.3. By Indication
13.4.4. By Distribution Channel
13.5. Drivers & Restraints Impact Analysis
13.6. Country-Wise Analysis
13.6.1. Brazil Market Analysis
13.6.1.1. Introduction
13.6.1.2. Market Analysis and Forecast by Market Taxonomy
13.6.1.2.1. By Drug Class
13.6.1.2.2. By Indication
13.6.1.2.3. By Distribution Channel
13.6.2. Peru Market Analysis
13.6.2.1. Introduction
13.6.2.2. Market Analysis and Forecast by Market Taxonomy
13.6.2.2.1. By Drug Class
13.6.2.2.2. By Indication
13.6.2.2.3. By Distribution Channel
13.6.3. Rest of Latin America Market Analysis
13.6.3.1. Introduction
13.6.3.2. Market Analysis and Forecast by Market Taxonomy
13.6.3.2.1. By Drug Class
13.6.3.2.2. By Indication
13.6.3.2.3. By Distribution Channel
14. China Market Analysis 2018 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023
14.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034
14.3.1. By Drug Class
14.3.2. By Indication
14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Drug Class
14.4.2. By Indication
14.4.3. By Distribution Channel
14.5. Drivers & Restraints Impact Analysis
15. South Asia and Pacific Market Analysis 2018 to 2023 and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023
15.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Malaysia
15.3.1.4. Vietnam
15.3.1.5. Afghanistan
15.3.1.6. Bangladesh
15.3.1.7. Cambodia
15.3.1.8. Myanmar
15.3.1.9. Nepal
15.3.1.10. Pakistan
15.3.2. By Drug Class
15.3.3. By Indication
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Indication
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Drivers & Restraints Impact Analysis
15.7. Key Market Players Intensity Mapping
15.8. PESTEL Analysis
15.9. Country-Wise Analysis
15.9.1. India Market Analysis
15.9.1.1. Introduction
15.9.1.2. Market Analysis and Forecast by Market Taxonomy
15.9.1.2.1. By Drug Class
15.9.1.2.2. By Indication
15.9.1.2.3. By Distribution Channel
15.9.2. Thailand Market Analysis
15.9.2.1. Introduction
15.9.2.2. Market Analysis and Forecast by Market Taxonomy
15.9.2.2.1. By Drug Class
15.9.2.2.2. By Indication
15.9.2.2.3. By Distribution Channel
15.9.3. Malaysia Market Analysis
15.9.3.1. Introduction
15.9.3.2. Market Analysis and Forecast by Market Taxonomy
15.9.3.2.1. By Drug Class
15.9.3.2.2. By Indication
15.9.3.2.3. By Distribution Channel
15.9.4. Vietnam Market Analysis
15.9.4.1. Introduction
15.9.4.2. Market Analysis and Forecast by Market Taxonomy
15.9.4.2.1. By Drug Class
15.9.4.2.2. By Indication
15.9.4.2.3. By Distribution Channel
15.9.5. Afghanistan Market Analysis
15.9.5.1. Introduction
15.9.5.2. Market Analysis and Forecast by Market Taxonomy
15.9.5.2.1. By Drug Class
15.9.5.2.2. By Indication
15.9.5.2.3. By Distribution Channel
15.9.6. Bangladesh Market Analysis
15.9.6.1. Introduction
15.9.6.2. Market Analysis and Forecast by Market Taxonomy
15.9.6.2.1. By Drug Class
15.9.6.2.2. By Indication
15.9.6.2.3. By Distribution Channel
15.9.7. Cambodia Market Analysis
15.9.7.1. Introduction
15.9.7.2. Market Analysis and Forecast by Market Taxonomy
15.9.7.2.1. By Drug Class
15.9.7.2.2. By Indication
15.9.7.2.3. By Distribution Channel
15.9.8. Myanmar Market Analysis
15.9.8.1. Introduction
15.9.8.2. Market Analysis and Forecast by Market Taxonomy
15.9.8.2.1. By Drug Class
15.9.8.2.2. By Indication
15.9.8.2.3. By Distribution Channel
15.9.9. Nepal Market Analysis
15.9.9.1. Introduction
15.9.9.2. Market Analysis and Forecast by Market Taxonomy
15.9.9.2.1. By Drug Class
15.9.9.2.2. By Indication
15.9.9.2.3. By Distribution Channel
15.9.10. Pakistan Market Analysis
15.9.10.1. Introduction
15.9.10.2. Market Analysis and Forecast by Market Taxonomy
15.9.10.2.1. By Drug Class
15.9.10.2.2. By Indication
15.10. By Distribution Channel
16. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023
16.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034
16.3.1. By Country
16.3.1.1. Ukraine
16.3.1.2. Armenia
16.3.1.3. Georgia
16.3.2. By Drug Class
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Indication
16.4.4. By Distribution Channel
16.5. Drivers & Restraints Impact Analysis
16.6. Country-Wise Analysis
16.6.1. Ukraine Market Analysis
16.6.1.1. Introduction
16.6.1.2. Market Analysis and Forecast by Market Taxonomy
16.6.1.2.1. By Drug Class
16.6.1.2.2. By Indication
16.6.1.2.3. By Distribution Channel
16.6.2. Armenia Market Analysis
16.6.2.1. Introduction
16.6.2.2. Market Analysis and Forecast by Market Taxonomy
16.6.2.2.1. By Drug Class
16.6.2.2.2. By Indication
16.6.2.2.3. By Distribution Channel
16.6.3. Georgia Market Analysis
16.6.3.1. Introduction
16.6.3.2. Market Analysis and Forecast by Market Taxonomy
16.6.3.2.1. By Drug Class
16.6.3.2.2. By Indication
16.6.3.2.3. By Distribution Channel
17. Central Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023
17.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034
17.3.1. By Country
17.3.1.1. Kazakhstan
17.3.1.2. Kyrgyzstan
17.3.1.3. Tajikistan
17.3.1.4. Rest of Central Asia
17.3.2. By Drug Class
17.3.3. By Indication
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Indication
17.4.4. By Distribution Channel
17.5. Drivers & Restraints Impact Analysis
17.6. Country-Wise Analysis
17.6.1. Kazakhstan Market Analysis
17.6.1.1. Introduction
17.6.1.2. Market Analysis and Forecast by Market Taxonomy
17.6.1.2.1. By Drug Class
17.6.1.2.2. By Indication
17.6.1.2.3. By Distribution Channel
17.6.2. Kyrgyzstan Market Analysis
17.6.2.1. Introduction
17.6.2.2. Market Analysis and Forecast by Market Taxonomy
17.6.2.2.1. By Drug Class
17.6.2.2.2. By Indication
17.6.2.2.3. By Distribution Channel
17.6.3. Tajikistan Market Analysis
17.6.3.1. Introduction
17.6.3.2. Market Analysis and Forecast by Market Taxonomy
17.6.3.2.1. By Drug Class
17.6.3.2.2. By Indication
17.6.3.2.3. By Distribution Channel
18. Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023
18.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034
18.3.1. By Country
18.3.1.1. Kenya
18.3.1.2. Egypt
18.3.1.3. South Africa
18.3.1.4. Nigeria
18.3.1.5. Cote d'Ivoire
18.3.1.6. Ghana
18.3.1.7. Mozambique
18.3.1.8. Senegal
18.3.1.9. Tanzania
18.3.1.10. Uganda
18.3.2. By Drug Class
18.3.3. By Indication
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Class
18.4.3. By Indication
18.4.4. By Distribution Channel
18.5. Drivers & Restraints Impact Analysis
18.6. Country Level Analysis
18.6.1. Kenya Market Analysis
18.6.1.1. Introduction
18.6.1.2. Market Analysis and Forecast by Market Taxonomy
18.6.1.2.1. By Drug Class
18.6.1.2.2. By Indication
18.6.1.2.3. By Distribution Channel
18.6.2. Egypt Market Analysis
18.6.2.1. Introduction
18.6.2.2. Market Analysis and Forecast by Market Taxonomy
18.6.2.2.1. By Drug Class
18.6.2.2.2. By Indication
18.6.2.2.3. By Distribution Channel
18.6.3. South Africa Market Analysis
18.6.3.1. Introduction
18.6.3.2. Market Analysis and Forecast by Market Taxonomy
18.6.3.2.1. By Drug Class
18.6.3.2.2. By Indication
18.6.3.2.3. By Distribution Channel
18.6.4. Nigeria Market Analysis
18.6.4.1. Introduction
18.6.4.2. Market Analysis and Forecast by Market Taxonomy
18.6.4.2.1. By Drug Class
18.6.4.2.2. By Indication
18.6.4.2.3. By Distribution Channel
18.6.5. Cote d'Ivoire Market Analysis
18.6.5.1. Introduction
18.6.5.2. Market Analysis and Forecast by Market Taxonomy
18.6.5.2.1. By Drug Class
18.6.5.2.2. By Indication
18.6.5.2.3. By Distribution Channel
18.6.6. Ghana Market Analysis
18.6.6.1. Introduction
18.6.6.2. Market Analysis and Forecast by Market Taxonomy
18.6.6.2.1. By Drug Class
18.6.6.2.2. By Indication
18.6.6.2.3. By Distribution Channel
18.6.7. Mozambique Market Analysis
18.6.7.1. Introduction
18.6.7.2. Market Analysis and Forecast by Market Taxonomy
18.6.7.2.1. By Drug Class
18.6.7.2.2. By Indication
18.6.7.2.3. By Distribution Channel
18.6.8. Senegal Market Analysis
18.6.8.1. Introduction
18.6.8.2. Market Analysis and Forecast by Market Taxonomy
18.6.8.2.1. By Drug Class
18.6.8.2.2. By Indication
18.6.8.2.3. By Distribution Channel
18.6.9. Tanzania Market Analysis
18.6.9.1. Introduction
18.6.9.2. Market Analysis and Forecast by Market Taxonomy
18.6.9.2.1. By Drug Class
18.6.9.2.2. By Indication
18.6.9.2.3. By Distribution Channel
18.6.10. Uganda Market Analysis
18.6.10.1. Introduction
18.6.10.2. Market Analysis and Forecast by Market Taxonomy
18.6.10.2.1. By Drug Class
18.6.10.2.2. By Indication
18.6.10.2.3. By Distribution Channel
19. Rest of Countries Market Analysis 2018–2023 and Forecast 2024 to 2034
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023
19.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034
19.3.1. By Drug Class
19.3.2. By Indication
19.3.3. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug Class
19.4.3. By Indication
19.4.4. By Distribution Channel
19.5. Drivers & Restraints Impact Analysis
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players (%)
20.3. Market Presence Analysis
20.3.1. Regional footprint of Players
20.3.2. Platform Type foot print by Players
20.3.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Branding and Promotional Strategies, By Key Manufactures
21.4. Key Development Analysis
21.5. Competition Deep Dive
21.5.1. Pfizer Inc.
21.5.1.1. Overview
21.5.1.2. Drug Pipeline Portfolio
21.5.1.3. Key Financials
21.5.1.4. SWOT Analysis
21.5.1.5. Key Developments
21.5.1.6. Sales Footprint
21.5.1.7. Strategy Overview
21.5.1.7.1. Marketing Strategy
21.5.1.7.2. Product Strategy
21.5.1.7.3. Channel Strategy
21.5.2. Takeda Pharmaceuticals
21.5.3. Alkermes, Inc
21.5.4. Hikma Pharmaceuticals
21.5.5. Emergent BioSolutions Inc.
21.5.6. Indivior Inc.
21.5.7. Mundipharma GmbH
21.5.8. Purdue Pharma LP
21.5.9. Orexo US, Inc.
21.5.10. Boehringer Ingelheim
21.5.11. Jamp Pharma Corporation
21.5.12. Vistapharm, Inc.
21.5.13. Atlantic Biologicals Corp.
21.5.14. BLISTECO S.A.S.
21.5.15. BioDelivery Sciences International Inc
21.5.16. Purdue Pharma
21.5.17. Braeburn Inc.
21.5.18. Camurus Ab
21.5.19. Knight Therapeutics Inc.
21.5.20. Titan Pharmaceuticals, Inc.
21.5.21. Braeburn Pharmaceuticals
21.5.22. L. Molteni & C. Dei Fratelli Alitti Società Di Esercizio S.P.A.
21.5.23. Sterinova Inc
21.5.24. Teva Pharmaceutical Industries Ltd.
21.5.25. USWM, LLC.
21.5.26. Wellona Pharma
21.5.27. Taj Pharmaceuticals Limited
21.5.28. Livealth Biopharma Pvt Ltd
21.5.29. Somerset Therapeutics Limited
21.5.30. Walter Healthcare Private Limited
21.5.31. Mallinckrodt Pharmaceuticals
21.5.32. Rusan Pharma Ltd
21.5.33. Viatris Inc
21.5.34. RINQUE PHARMA.
21.5.35. Par Pharmaceutical
21.5.36. The Bristol-Myers Squibb Company
21.5.37. Intas Pharmaceuticals
21.5.38. STERIS PHARMA
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Low and Middle Income Countries Opioid Substitution Therapy Market
